This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Dr. Kevin Foley To Present DiscGenic's Recent Findings At The Lumbar Spine Research Society's Annual Meeting

SALT LAKE CITY, April 3, 2013 /PRNewswire/ -- DiscGenics, Inc. announces that Kevin T. Foley, MD will present at the upcoming Lumbar Spine Research Society (LSRS) Annual Meeting on April 12, 2013 in Chicago. The lecture, entitled "Initial  In Vivo Efficacy of a Novel, Injectable Cellular Therapy for Degenerative Disc Disease," will feature data supporting the safety and efficacy of a new therapy under development called Injectable Discogenic Cell Therapy (IDCT) in an animal model of degenerative disc disease.

Dr. Foley, who is the senior author on the work, is a professor of neurosurgery at the University of Tennessee Health Science Center in Memphis, Tennessee, USA. He holds academic appointments at the University of Tennessee Department of Biomedical Engineering and the Uniformed Services University for the Health Sciences in Bethesda, Maryland. He serves as director of complex spine surgery at Semmes-Murphey Clinic, director of the spine fellowship program for the University of Tennessee Department of Neurosurgery, and medical director for the Medical Education & Research Institute. 

About DiscGenics, Inc.

DiscGenics is a privately funded spinal therapeutics company using adult human disc-derived stem cells and tissue engineering techniques to treat patients debilitated by degenerative disc disease. News and other information on the company are available at: http://www.discgenics.com .

Media Contact: Flagg Flanagan Chief Executive Officer 801-410-0703 flagg@discgenics.com

SOURCE DiscGenics, Inc.

Copyright 2011 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 17,826.30 -279.47 -1.54%
S&P 500 2,081.18 -23.81 -1.13%
NASDAQ 4,931.8150 -75.9760 -1.52%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs